Retraction: αB-Crystallin, an Effector of Unfolded Protein Response, Confers Anti-VEGF Resistance to Breast Cancer via Maintenance of Intracrine VEGF in Endothelial Cells (Mol Cancer Res (2011) 9 (1632–1643) DOI: 10.1158/1541-7786.MCR-11-0327);αB-crystallin, an effector of unfolded protein response, confers anti-VEGF resistance to breast cancer via maintenance of intracrine VEGF in endothelial cells

Molecular Cancer Research

Volumn 9, Issue 12, 2011, Pages 1632-1643

  Ruan, Qing ^a   Han, Song ^b   Jiang, Wen G ^c   Boulton, Michael E ^a   Chen, Zhi J ^a   Law, Brian K ^a   Cai, Jun ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CRYSTALLIN; CHAPERONE; SMALL INTERFERING RNA; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOCRINE EFFECT; BREAST CANCER; CANCER RESISTANCE; CANCER SURVIVAL; CELL ACTIVATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; UNFOLDED PROTEIN RESPONSE; UPREGULATION; XENOGRAFT;

EID: 84055216939     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-22-0454     Document Type: Erratum

References (38)

1. Espinosa E, Vara JA, Navarro IS, Gámez-Pozo A, Pinto A, Zamora P, et al. Gene profiling in breast cancer: time to move forward. Cancer Treat Rev 2011;37:416-21.
2. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008;14:1368-76. (Pubitemid 351413917)
3. Kennedy CR, Gao F, Margenthaler JA. Neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer. J Surg Res 2010; 163:52-7.
4. Burstein HJ, Chen YH, Parker LM, Savoie J, Younger J, Kuter I, et al. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res 2008;14:7871-7.
5. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008; 26:4672-8.
6. Nieto Y, Woods J, Nawaz F, Baron A, Jones RB, Shpall EJ, et al. Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy. Br J Cancer 2007;97:391-7. (Pubitemid 47196747)
7. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34. (Pubitemid 47219710)
8. Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, et al. A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res 2008;14: 7878-83.
9. Valachis A, Polyzos NP, Patsopoulos NA, Georgoulias V, Mavroudis D, Mauri D. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat 2010;122:1-7.
10. Kerbel RS. Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer. Breast 2009;18 Suppl 3: S41-7.
11. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74. (Pubitemid 32878711)
12. Stegh AH, Kesari S,Mahoney JE, Jenq HT, Forloney KL, Protopopov A, et al. Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma. Proc Natl Acad Sci U S A 2008;105:10703-8.
13. Moyano JV, Evans JR, Chen F, Lu M, Werner ME, Yehiely F, et al. AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 2006;116:261-70. (Pubitemid 43121811)
14. Lowe J, McDermott H, Pike I, Spendlove I, Landon M, Mayer RJ. alpha Bcrystallin expression in non-lenticular tissues and selective presence in ubiquitinated inclusion bodies in human disease. J Pathol 1992; 166:61-8.
15. Singh BN, Rao KS, Rao Ch M. Ubiquitin-proteasome-mediated degradation and synthesis of MyoD is modulated by alphaB-crystallin, a small heat shock protein, during muscle differentiation. Biochim Biophys Acta 2010;1803:288-99.
16. Liu L, Ghosh JG, Clark JI, Jiang S. Studies of alphaB crystallin subunit dynamics by surface plasmon resonance. Anal Biochem 2006;350: 186-95. (Pubitemid 43332818)
17. Kase S, He S, Sonoda S, Kitamura M, Spee C, Wawrousek E, et al. alphaB-crystallin regulation of angiogenesis by modulation of VEGF. Blood 2010;115:3398-406.
18. Dimberg A, Rylova S, Dieterich LC,OlssonAK, Schiller P, Wikner C, et al. alphaB-crystallin promotes tumor angiogenesis by increasing vascular survival during tube morphogenesis. Blood 2008;111:2015-23. (Pubitemid 351451512)
19. Lacroix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 2004;83: 249-89. (Pubitemid 38264873)
20. Cai J, Jiang WG, Grant MB, Boulton M. Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J Biol Chem 2006;281: 3604-13. (Pubitemid 43845978)
21. Heiring C, Muller YA. Folding screening assayed by proteolysis: application to various cystine deletion mutants of vascular endothelial growth factor. Protein Eng 2001;14:183-8. (Pubitemid 32487972)
22. Cai J, Parr C, Watkins G, Jiang WG, Boulton M. Decreased pigment epithelium-derived factor expression in human breast cancer progression. Clin Cancer Res 2006;12:3510-7.
23. Jiang WG, Davies G, Martin TA, Parr C, Watkins G, Mason MD, et al. Targeting matrilysin and its impact on tumor growth in vivo: the potential implications in breast cancer therapy. Clin Cancer Res 2005;11:6012-9. (Pubitemid 41170333)
24. Naidoo N. ER and aging-protein folding and the ER stress response. Ageing Res Rev 2009;8:150-9.
25. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007;8:519-29. (Pubitemid 46985379)
26. Ousman SS, Tomooka BH, van Noort JM, Wawrousek EF, O'Connor KC, Hafler DA, et al. Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination. Nature 2007;448:474-9. (Pubitemid 47123511)
27. Al-Nedawi K, Meehan B, Kerbel RS, Allison AC, Rak J. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc Natl Acad Sci U S A 2009;106:3794-9.
28. Gerber HP, Ferrara N. The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med 2003;81:20-31. (Pubitemid 36207880)
29. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007;130:691-703. (Pubitemid 47268059)
30. Finger EC, Giaccia AJ. Hypoxia, inflammation, and the tumor micro-environment in metastatic disease. Cancer Metastasis Rev 2010;29: 285-93.
31. Ha Y, Choi JU, Yoon DH, Cho YE, Kim TS. Nestin and small heat shock protein expression on reactive astrocytes and endothelial cells in cerebral abscess. Neurosci Res 2002;44:207-12. (Pubitemid 38365962)
32. Xu Q. Role of heat shock proteins in atherosclerosis. Arterioscler Thromb Vasc Biol 2002;22:1547-59.
33. Ecroyd H, Carver JA. The effect of small molecules in modulating the chaperone activity of alphaB-crystallin against ordered and disordered protein aggregation. FEBS J 2008;275:935-47. (Pubitemid 351230209)
34. Ghosh JG, Shenoy AK Jr., Clark JI. Interactions between important regulatory proteins and human alphaB crystallin. Biochemistry 2007; 46:6308-17. (Pubitemid 46842874)
35. Yehiely F, Moyano JV, Evans JR, Nielsen TO, Cryns VL. Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med 2006;12:537-44. (Pubitemid 44740239)
36. Gerber HP, Malik AK, Solar GP, Sherman D, Liang XH, Meng G, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002;417:954-8. (Pubitemid 34716872)
37. Browder TM, Abrams JS, Wong PM, Nienhuis AW. Mechanism of autocrine stimulation in hematopoietic cells producing interleukin-3 after retrovirus-mediated gene transfer. Mol Cell Biol 1989;9: 204-13. (Pubitemid 19024792)
38. Maharaj AS, Saint-Geniez M, Maldonado AE, D'Amore PA. Vascular endothelial growth factor localization in the adult. Am J Pathol 2006;168:639-48. (Pubitemid 43271161)